Lyra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Lyra Therapeutics

29/03/2023 22:19

* Lyra Therapeutics Inc  LYRA.OQ  reported a quarterly
adjusted
loss of 38 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 41 cents per share.
    * Revenue fell 95.9% to $11.00 thousand from a year ago;
analysts
expected $151.80 thousand. 
    * Lyra Therapeutics Inc's reported EPS for the quarter was a
loss
of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Lyra Therapeutics Inc shares had fallen by 37.6% this
quarter.
    * The company reported a quarterly loss of $14.24 million.
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $16.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 29 at 09:18 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.41          -0.38          Beat
 Sep. 30 2022      -0.44          -0.40          Beat
 Jun. 30 2022      -0.37          -0.43          Missed
 Mar. 31 2022      -0.91          -0.54          Beat